0000000000326487

AUTHOR

Fabio Monari

showing 4 related works from this author

High-Risk Patients with Differentiated Thyroid Cancer T4 Primary Tumors Achieve Remnant Ablation Equally Well Using rhTSH or Thyroid Hormone Withdraw…

2013

Few data exist on using thyrotropin alfa (recombinant human thyroid-stimulating hormone [rhTSH]) with radioiodine for thyroid remnant ablation of patients who have T4 primary tumors (invasion beyond the thyroid capsule).A retrospective chart review protocol at nine centers in Europe was set up with special waiver of need for informed consent, along with a careful procedure to avoid selection bias when enrolling patients into the database. Data on 144 eligible patients with T4 tumors were collected (T4, N0-1, M0-1; mean age 49.7 years; 65% female; 88% papillary cancer). All had received (131)I remnant ablation following TSH stimulation with rhTSH or thyroid hormone withdrawal (THW) since Jan…

AdultMalemedicine.medical_specialtyNeoplasm ResidualEndocrinology Diabetes and Metabolismmedicine.medical_treatmentUrologyRemnant ablationIodine RadioisotopesYoung AdultEndocrinologyClinical endpointmedicineHumansThyroid NeoplasmsThyrotropin AlfaThyroid cancerAgedRetrospective StudiesAged 80 and overHigh risk patientsbusiness.industryThyroidCancerMiddle Agedmedicine.diseaseAblationCombined Modality TherapySurgeryTreatment Outcomemedicine.anatomical_structureThyroidectomyFemalebusinessHormoneThyroid
researchProduct

Overall survival in mCPRC patients treated with Radium-223 in association with bone health agents: a national multicenter study

2020

Radium-223 has demonstrated efficacy in improving overall survival (OS) and in delaying symptomatic skeletal-related events (SREs). Bone Health Agents (BHA), i.e. RANK ligand inhibitor (Denosumab) and bisphosphonate such as zoledronic acid, are indicated to prevent SREs without a clear survival benefit. SREs on patient health have a high impact and it is, therefore, important to consider the role of new therapies with BHA to better understand the involvement of combination therapy. The primary aim of this multicentric study is to assess OS in mCRPC patients treated with Radium-223 in combination with BHA.430 consecutive patients treated with Radium-223 alone or in combination with BHA, affe…

MaleRadium-223Oncologymedicine.medical_specialtyRadium-223 dichlorideRadium-223 dichloride; bone health agents; mCRPC; overall survival; prostate canceroverall survivalBone healthBone and Bones030218 nuclear medicine & medical imaging03 medical and health sciencesProstate cancer0302 clinical medicineBone MarrowInternal medicinemedicineOverall survivalHumansRadiology Nuclear Medicine and imagingRadium-223 DichlorideNeoplasm MetastasisAgedL-Lactate DehydrogenaseRadiological and Ultrasound Technologybusiness.industrymCRPCAlkaline Phosphataseprostate cancermedicine.diseaseSurvival AnalysisRANK Ligand InhibitorProstatic Neoplasms Castration-ResistantDenosumabMulticenter studybone health agents030220 oncology & carcinogenesisSettore SECS-S/01businessRadiummedicine.drugInternational Journal of Radiation Biology
researchProduct

Radium-223 in mCPRC patients: a large real-life Italian multicenter study

2020

Background Radium-223 is a targeted alpha-particles therapy approved for the treatment of mCRPC patients with symptomatic bone metastases. To our knowledge we account for the largest cohort of mCRPC patients subjected to Radium-223 treatment in our country. We aim to describe in a real-life setting the largest cohort of mCRPC patients treated with Radium-223 ever taken into consideration. Methods 430 consecutive mCRPC patients were enrolled. Clinical data have been collected at baseline and at the end of the Radium-223 treatment. Furthermore, the overall survival(OS) of our population has been provided. Results 157 patients (36.5%) were still alive at the time of data analysis. A mean numbe…

MaleRadium-223radium-223; mCRPC; prostate cancer; target alpha therapyPediatricsmedicine.medical_specialtyradium-223UrologyPopulationBone NeoplasmsContext (language use)Quality of lifemedicineHumanseducationeducation.field_of_studybusiness.industrymCRPCprostate cancerProstatic Neoplasms Castration-ResistantRegimenSafety profileTreatment OutcomeItalyMulticenter studyNephrologyCohortQuality of LifeSettore SECS-S/01businesstarget alpha therapyRadiummedicine.drugMinerva Urology and Nephrology
researchProduct

Prognostic role of inflammatory biomarkers from peripheral blood and clinical factors in metastatic castration-resistant prostate cancer (mCRPC) pati…

2021

e17026 Background: Ra-223 is a treatment option for mCRPC pts with bone metastases according to the survival benefit observed compared to placebo in the ALSYMPCA trial. In the last years, many studies showed this benefit in the real-life pts is lower than that reported in the trial, probably due to a suboptimal selection of pts with poor prognostic characteristics. Therefore, the identification of prognostic factors to select mCRPC pts most likely to benefit from Ra-223 is needed. The multicentre retrospective BIO-Ra-223 study has investigated the prognostic role of peripheral blood immune cells and clinical factors to develop a novel prognostic score for mCRPC pts treated with Ra-223. Met…

OncologyRadium-223Cancer Researchmedicine.medical_specialtybusiness.industryTreatment optionsCastration resistantPlacebomedicine.diseaseInflammatory biomarkersPeripheral bloodProstate cancerSurvival benefitOncologyInternal medicinemedicinebusinessmedicine.drug
researchProduct